Endometrial carcinoma: Controversies in histopathological assessment of grade and tumour cell type

Journal of Clinical Pathology

Volumn 63, Issue 5, 2010, Pages 410-415

  Clarke, Blaise A ^a   Gilks, C Blake ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GRADING; CANCER SURVIVAL; CELL TYPE; ENDOMETRIUM CARCINOMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVIEW;

CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951664346     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.071225     Document Type: Review

References (38)

1. Soslow RA, Bissonnette JP, Wilton A, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007;31:979-987 (Pubitemid 47012293)
2. Zaino RJ, Kurman RJ, Diana KL, et al. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 1995;75:81-86
3. Cooper K, Evans M, Mount S. Biology and evolution of cervical squamous intraepithelial lesions: a hypothesis with diagnostic prognostic implications. Adv Anat Pathol 2003;10:200-203
4. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-1228 (Pubitemid 34411626)
5. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125-136
6. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-1716
7. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-104
8. Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008;109:11-18.
9. Kong A, Simera I, Collingwood M, et al. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol 2007;18:1595-1604 (Pubitemid 47506245)
10. Takeshima N, Hirai Y, Hasumi K. Prognostic validity of neoplastic cells with notable nuclear atypia in endometrial cancer. Obstet Gynecol 1998;92:119-123 (Pubitemid 28285333)
11. Taylor RR, Zeller J, Lieberman RW, et al. An analysis of two versus three grades for endometrial carcinoma. Gynecol Oncol 1999;74:3-6. (Pubitemid 29331160)
12. Lax SF, Kurman RJ, Pizer ES, et al. A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000;24:1201-1208
13. Scholten AN, Smit VT, Beerman H, et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 2004;100:764-772 (Pubitemid 38176855)
14. Alkushi A, Abdul-Rahman ZH, Lim P, et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 2005;29:295-304. (Pubitemid 40321964)
15. Scholten AN, Creutzberg CL, Noordijk EM, et al. Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system. Int J Radiat Oncol Biol Phys 2002;52:1067-1074
16. Gemer O, Uriev L, Voldarsky M, et al. The reproducibility of histological parameters employed in the novel binary grading systems of endometrial cancer. Eur J Surg Oncol 2009;35:247-251
17. Kapucuoglu N, Bulbul D, Tulunay G, et al. Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters. Int J Gynecol Cancer 2008;18:790-796 (Pubitemid 352020156)
18. Nedergaard L, Jacobsen M, Andersen JE. Interobserver agreement for tumour type, grade of differentiation and stage in endometrial carcinomas. APMIS 1995;103:511-518
19. Stefansson IM, Salvesen HB, Immervoll H, et al. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004;44:472-479 (Pubitemid 38725676)
20. Nielsen AL, Thomsen HK, Nyholm HC. Evaluation of the reproducibility of the revised 1988 International Federation of Gynecology and Obstetrics grading system of endometrial cancers with special emphasis on nuclear grading. Cancer 1991;68:2303-2309
21. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2002;9:145-184
22. Murray SK, Young RH, Scully RE. Uterine endometrioid carcinoma with small nonvillous papillae: an analysis of 26 cases of a favorable-prognosis tumor to be distinguished from serous carcinoma. Int J Surg Pathol 2000;8:279-289
23. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004;28:1568-1578 (Pubitemid 39564961)
24. Altrabulsi B, Malpica A, Deavers MT, et al. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 2005;29:1316-1321
25. Silva EG, Deavers MT, Bodurka DC, et al. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 2006;25:52-58
26. Garg K, Leitao MM Jr, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 2009;33:925-933
27. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998;29:551-558
28. Kovalev S, Marchenko ND, Gugliotta BG, et al. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol 1998;29:613-619 (Pubitemid 28272717)
29. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-1274
30. Soslow RA, Shen PU, Chung MH, et al. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998;17:129-134
31. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-185 (Pubitemid 27027108)
32. Crum CP, Lee KR, Mutter GL. Adenocarcinoma, carcinosarcoma and other epithelial tumors of the endometrium. In: Crum CP, Lee KR, eds. Diagnostic gynecologic and obstetric pathology. Philadelphia: Elsevier Saunders, 2006:547.
33. Alkushi A, Clarke BA, Akbari M, et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007;20:1156-1165 (Pubitemid 47609063)
34. Al Kushi A, Lim P, Aquino-Parsons C, et al. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 2002;15:365-371 (Pubitemid 34326943)
35. Yemelyanova A, Ji H, Shih IM, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009 33:1504-1514
36. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006;19:1091-1100 (Pubitemid 44106724)
37. Soslow RA, Shen PU, Chung MH, et al. Cyclin D1 expression in high-grade endometrial carcinomas-association with histologic subtype. Int J Gynecol Pathol 2000;19:329-334
38. Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002;15:1032-1037